Biogen
BIIB
$202.46
Share price
0.23%
Change (1 day)
-28.31%
Change (1 year)
Categories
Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
P/S ratio for Biogen (BIIB)
P/S ratio as of April 2024 (TTM): 2.99
According to Biogen's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.99217. At the end of 2023 the company had a P/S ratio of 3.81.
P/S ratio history for Biogen from 2004 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 3.81 | -2.74% |
| 2022 | 3.92 | 22.14% |
| 2021 | 3.21 | 14.51% |
| 2020 | 2.80 | -22.05% |
| 2019 | 3.60 | -18.5% |
| 2018 | 4.41 | -19.64% |
| 2017 | 5.49 | 1.85% |
| 2016 | 5.39 | -13.38% |
| 2015 | 6.22 | -24.18% |
| 2014 | 8.21 | -13.91% |
| 2013 | 9.53 | 75.42% |
| 2012 | 5.43 | -2.81% |
| 2011 | 5.59 | 63.48% |
| 2010 | 3.42 | 1.79% |
| 2009 | 3.36 | 0.33% |
| 2008 | 3.35 | -36.91% |
| 2007 | 5.31 | -40.09% |
| 2006 | 8.86 | -1.23% |
| 2005 | 8.97 | -36.76% |
| 2004 | 14.2 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 3.85 | 28.59% | 🇺🇸 USA |
 Pfizer PFE | 2.54 | -15.01% | 🇺🇸 USA |
 AbbVie ABBV | 5.47 | 82.81% | 🇺🇸 USA |
 Amgen AMGN | 5.19 | 73.61% | 🇺🇸 USA |
 Sanofi SNY | 2.45 | -18.22% | 🇫🇷 France |
 Gilead Sciences GILD | 3.08 | 3.10% | 🇺🇸 USA |
 Illumina ILMN | 4.28 | 43.05% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | 0.0070 | -99.77% | 🇺🇸 USA |
 Qiagen QGEN | 4.68 | 56.29% | 🇳🇱 Netherlands |
 Bio-Rad Laboratories BIO | 2.97 | -0.63% | 🇺🇸 USA |